New agents for cancer immunotherapy: 4SC m⁴ receives grant

The Martinsried-based biotech company 4SC AG announced today that it will receive project funding of 600,000 euros by the Federal Ministry for education and research (BMBF). The project in the framework of Leading-Edge Cluster m4 - personalized medicine aims for the preclinical development of TLR7 and TLR8 agonists. The toll-like receptors (TLRs) are part of the innate immune system. They serve to recognize foreign molecules,  for example bacterial or viral DNA, and trigger an immune response. An efficient immune response against cancer cells is to be achieved through an agonistic activation of TLRs with small molecules.

4SC is a specialist for the development of targeted, small molecules against cancer and autoimmune diseases. Cooperation partner of the project is the group of immune pharmacology (Dr. Sebastian Kobold) of the Department of Clinical Pharmacology (head Professor Dr. Stefan Endres) in the university hospital of the Ludwig-Maximilians-Universität Munich.

To the press release of 4SC